Anti-TNF-α agents have demonstrated promising effects in reducing CV risk, thromboembolic events, and overall mortality in IBD patients, although their influence on lipid profiles remains uncertain [269,275,277,280,281]. The gene discussed is TNF; the disease is inflammatory bowel disease.